Company* |
Product |
Description |
Indication |
Status (Date) |
| | ||||
AUTOIMMUNE | ||||
Advanced Biotherapy Inc. (OTC BB:ADVB) |
-- |
Antibodies to block interferon-gamma |
Severe rheumatoid arthritis |
55-patient trial in Moscow showed beneficial effects of using IFN-gamma to treat RA (9/30) |
|
||||
Cambridge Antibody Technology Group plc (UK; CATG; LSE:CAT) and Abbott Laboratories |
Humira (FDA-approved) |
Adalimumab |
Rheumatoid arthritis |
Companies received approval in Europe to market Humira (9/10) |
|
||||
CANCER | ||||
Bioenvision Inc. |
Clofarabine |
Second-generation purine nucleoside antimetabolite |
Acute lympho- blastic leukemia |
Company began a pivotal Phase II study in Europe (9/16) |
|
||||
Lorus Therapeutics Inc. (Canada; OTC BB:LORFF) |
GTI-2040 |
Antisense drug that specifically targets the R2 component of ribonucleotide reductase |
Non-small-cell lung cancer |
Health Canada granted approval for the initiation of a clinical trial of GTI-2040 in combination with docetaxel (9/15) |
|
||||
Lorus Therapeutics Inc. (Canada; OTC BB:LORFF) |
Virulizin |
Cancer agent |
Advanced pancreatic cancer |
Expanded Phase III trial to include sites in Europe and South America; trial entails combination therapy (9/30) |
|
||||
CARDIOVASCULAR | ||||
United Therapeutics Corp. (UTHR) |
Remodulin (FDA-approved) |
Treprostinil sodium injection |
Pulmonary arterial hypertension |
French authorities, acting as reference nation, rejected approval (9/22) |
|
||||
CENTRAL NERVOUS SYSTEM | ||||
Genzyme Corp. (GENZ) |
Synvisc (FDA-approved) |
Hylan G-F 20 |
Pain from osteoarthritis |
Company filed for Japanese approval (9/4) |
|
||||
Indevus Inc. (IDEV) |
IP 751 (CT-3) |
Synthetic cannabinoid |
Neuropathic pain |
Data from 21-patient Phase II trial in Germany showed significant reduction of degree of neuropathic pain without psychoactive adverse events (9/30) |
|
||||
Proneuron Biotechnologies Inc.* |
Copolymer-1 |
COP-1; Copaxone |
Huntington's disease |
Company began a Phase II trial in Israel (9/22) |
|
||||
DIABETES | ||||
Generex Biotechnology Corp. (Canada; GNBT) |
Oralin |
Oral insulin spray formulation |
Type II diabetes |
Company began a Phase IIb trial of Oralin in Canada (9/18) |
|
||||
INFECTION | ||||
Corixa Corp. (CRXA) |
Supervax |
A prophylactic hepatitis B vaccine that combines Corixa's synthetic RC-529 adjuvant with the Hansenula polymorpha-based recombinant hepatitis B antigen |
Hepatitis B |
Company received approval in Argentina for Supervax (9/9) |
|
||||
Sicor Biotech UAB (subsidiary of Sicor Inc.; SCRI) |
Grasalva |
Filgrastim; recombinant human granulocyte colony-stimulating factor |
To fight infections |
Company received approval in Lithuania for Grasalva (9/2) |
|
||||
MISCELLANEOUS | ||||
Genesis Research and Development Corp. (New Zealand; NZSE: GEN) and SR Pharma plc (UK; LSE SPA) |
AVAC |
Derivative of M. vaccae |
Atopic dermatitis |
Companies began a Phase II trial in children in New Zealand (9/10) |
|
||||
Genzyme Corp. (GENZ) |
Cerezyme (FDA-approved) |
Imiglucerase |
Type 3 Gaucher's disease |
European Commission authorized an expanded indication for Cerezyme (9/15) |
|
||||
Nastech |
Peptide YY3-36 |
Intranasal version |
Obesity |
Company initiated Phase I study in UK to assess nasal absorption and safety in healthy volunteers (9/23) |
|
||||
Unigene Laboratories Inc. (OTC BB:UGNE) |
Calcitonin products |
Nasal and injectable formulations |
Osteoporosis |
Company filed an NDA in China (9/4) |
|
||||
|
| ||||
Notes: | ||||
* Privately held | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; FSE = Frankfort Stock Exchange; LSE = London Stock Exchange; NZSE = New Zealand Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.